These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38058210)

  • 1. Differences in venous clot structures between hemophilic mice treated with emicizumab
    Sefiane T; Maynadié H; Ettingshausen CE; Muczynski V; Heiligenstein X; Dumont J; Christophe OD; Denis CV; Casari C; Lenting PJ
    Haematologica; 2024 Jun; 109(6):1836-1848. PubMed ID: 38058210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
    Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
    Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
    J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
    Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Lenting PJ; Denis CV; Christophe OD
    Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
    Nakajima Y; Nogami K; Yada K; Furukawa S; Noguchi-Sasaki M; Hirata M; Shima M
    Thromb Haemost; 2020 Jun; 120(6):968-976. PubMed ID: 32384547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
    Josset L; Leuci A; Janbain M; De-Wreede A; Desage S; Lienhart A; Bin V; Lebert D; Delavenne X; Dargaud Y
    J Thromb Haemost; 2024 Jul; 22(7):1857-1866. PubMed ID: 38583717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A.
    Bertaggia Calderara D; Marchi Cappelletti R; Batista Mesquita Sauvage AP; Durual S; Gomez FJ; Zermatten MG; Aliotta A; Casini A; Alberio L
    Thromb Haemost; 2023 Oct; 123(10):955-965. PubMed ID: 37336473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
    Bowyer AE; Maclean RM; Kitchen S
    Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
    Yada K; Nogami K
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe.
    Mancuso ME; Castaman G; Pochopien M; Aballéa S; Drzewiecka A; Hakimi Z; Nazir J; Fatoye F
    J Med Econ; 2022; 25(1):1068-1075. PubMed ID: 35993970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
    Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K
    Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.